Can I Participate?

If you’ve been diagnosed with epilepsy, you may be eligible to participate in the
X-TOLE2/X-TOLE3, or X-ACKT studies.

Eligibility criteria for those who have focal onset seizures (FOS) include:
You may be able to participate in the X-TOLE2/X-TOLE3 study for focal onset seizures if you:
Are 18 years of age or older
Have a confirmed diagnosis of focal onset seizures (FOS) for two or more years
Are on a stable dose of 1-3 anti-seizure medications (ASMs)
Have tried at least 2 anti-seizure medications (ASMs) but are still experiencing seizures
Eligibility criteria for those who have primary generalized epilepsy include:
You may be able to participate in the X-ACKT study for primary generalized tonic clonic seizures if you:
Are 12 years of age or older*
Have experienced primary generalized tonic-clonic seizures (PGTCS) for at least 1 year
Are on a stable dose of 1-3 anti-seizure medications (ASMs)
Have tried at least 2 anti-seizure medications (ASMs) but are still experiencing seizures

* If you are under 18 years old, your legal guardian must complete the questionnaire for you. PatientWing does not allow or accept questionnaires from anyone under the age of 18.

Other eligibility criteria apply.

What You May Receive

By enrolling in one of these epilepsy studies, you may receive:  

Study medication at no cost 

Study related medical care for epilepsy  

Stipends for study visits

Reimbursements for travel accommodations

Your study doctor will provide more information about what you may receive if you choose to participate in this study after your initial conversation with him/her.

Why Should I Participate?

By joining one of these clinical studies, you could contribute to advancements in medical knowledge and potentially help improve treatments and therapies for patients like yourself. Your participation can make a significant impact on epilepsy healthcare. 

You will be seen by experts who have experience treating people with epilepsy, and your involvement in one of these studies may lead to advancements in epilepsy research, understanding, and treatments.

See if You May Qualify

What's Involved?

Step 1

Express Interest

Click here to see if you may qualify for one of the three studies.

Step 2

Phone Call with PatientWing

If initially eligible, a PatientWing representative will call you to discuss the studies, additional eligibility criteria,
and answer your questions. If you are still eligible at the end of this screening call, you will be connected to a member of the team at a research site location for additional screening.

Step 3

Screening at the Research Site

The team at a participating research site will determine if you are eligible to participate in the study.

Step 4


The study will last for about 7 months, broken down into three different time periods. The screening period will last up to 9.5 weeks, and the treatment period will last up to 12 weeks. Participants in the study will be required to keep an accurate seizure diary throughout the study. After the initial 12 weeks, there will be an opportunity for participants to receive the study medication for up to 3 years in an open label extension study, if you and the study team decide it is best.

Getting Started

To start your questionnaire, we need to know what type of seizures you have so we can determine which study would be the better option. Please note - each study is only looking for patients who have focal onset seizures or primary generalized tonic-clonic seizures.  

Please select what type of seizures you have:

Select one of the following four options to proceed to our short questionnaire:

If you are unsure what type of seizures you have, you can still apply! Our team will contact you to discuss your medical history and if you pre-qualify, you’ll be connected with a research site to evaluate your eligibility for one of these studies. 

Differences Between FOS & PGTCS

These studies focus on two types of seizures: focal-onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Learn more about the differences between the two below:  

Focal onset seizures (FOS)  

Other names include partial seizures, complex partial seizures, focal seizure, focal epilepsy.

Focal onset seizures (FOS) start on one side of the brain and may or may not cause loss of awareness. They are the most common types of seizures in people with epilepsy.

Primary generalized tonic-clonic seizures (PGTCS)  

Other names include generalized epilepsy, tonic-clonic seizures, idiopathic generalized epilepsy, epilepsy with generalized tonic-clonic seizures.

Primary generalized tonic-clonic seizures originate on both sides of the brain simultaneously and are characterized by loss of awareness and rhythmic whole body muscle contractions.

For Loved Ones

The family, friends, and healthcare teams of those with epilepsy play an important role in supporting their loved one's health and wellbeing.

If you are a loved one of someone with epilepsy, you can apply to the study on their behalf by clicking the button below. You have the option to either enter the patient's information or your own contact information. Please obtain approval from the patient prior to entering their information.

Frequently Asked Questions

How do I get started?

Click “See if You May Qualify”, answer the question, and complete the questionnaire to express interest in the study.

Where are these studies conducted?

These studies are being conducted globally at different research sites. PatientWing will help identify the best site for you to visit.

How will the investigational medication be taken?

The study medication, XEN1101, or a placebo will be taken orally (by mouth) once daily for 12 weeks.

What is the study drug being tested?

The study drug being tested is XEN1101.

Has the study drug been tested before?

The study medication, XEN1101, has been previously tested and is undergoing continuous testing for safety and efficacy.

Is there a chance I will receive a placebo?

Yes, there is a chance you will receive a placebo instead of the study medication, XEN1101. For the X-ACKT (PGTCS) study, there is a 50% chance of receiving the study medication and a 50% chance of receiving the placebo. For the X-TOLE2 and X-TOLE3 (FOS) studies, there is a 66% chance of receiving the study medication and a 33% chance of receiving the placebo. There will be an opportunity for participants who qualify to participate in the Open Label Extension (OLE) study where they will receive the actual study medication for up to 3 years if you and the study team decide it is best.

Why didn’t I qualify?

Research studies are designed in specific ways to test the study drug for safety and effectiveness. An answer you provided was outside the guidelines for participating in this trial. This does not mean you will not qualify for other research studies.

Will I have access to the study medication after the study ends?

You may have the opportunity to receive continued study medication during the Open Label Extension (OLE) study. Your study doctor will be able to provide more information and answer any questions you may have during your Screening Visit. During the OLE, all enrolled patients will get XEN1101 and there is no placebo.

About Study Team

About The Sponsor

Xenon Pharmaceuticals is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. As the sponsor, Xenon is supporting these studies financially. The sponsor will not receive any potential participant personal data. To learn more, visit

About Us

Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our expertise in navigating the enrollment process, we're here for you every step of the way. To learn more, visit

Have questions?

We’re here to help!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
See If You May Qualify